Clinical trials for Prostate cancer

152 currently recruiting clinical trials

Phase 3 Prostate cancer #NCT06764485
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Celgene
Phase 3 Prostate cancer #NCT06136650 #2023-504957-11-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Prostate cancer #NCT07028853 #2024-519369-24-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
11 recruiting sites
Pfizer
Phase 3 Prostate cancer #NCT07225946 #2025-522713-29-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
7 recruiting sites
Janssen
Phase 3 Prostate cancer #NCT06626022
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at localized stage
Systemic Treatment-Naive Surgery Targeted therapy Radiotherapy Hormone therapy Internal Vectorised Radiotherapy (IVR)
1 recruiting site
University of Alberta
Phase 3 Prostate cancer #NCT07164443
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Janssen
Phase 3 Prostate cancer #NCT06629779 #2024-511652-40-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Pfizer
Phase 3 Prostate cancer #NCT06925737 #2024-517423-40-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Prostate cancer #NCT07213674 #2025-520555-89-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Amgen
Phase 3 Prostate cancer #NCT06952803 #2024-513586-39-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Biochemical recurrence
Required genetic anomalies
BRCA 1/2
Required previous treatments at localized stage
Radiotherapy Hormone therapy
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Targeted therapy
20 recruiting sites
AstraZeneca